InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,258.80
(
0.00%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.81
(
-0.24%
)
Bitcoin
64,592.15
(
-0.35%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: kamehameha post# 131276

Thursday, 11/17/2011 7:48:03 AM

Thursday, November 17, 2011 7:48:03 AM

Post# of 252279
VRUS/PSI-7977 phase III program

Not only in GT2/3: the NEUTRINO trial will enroll all genotypes who can not take interferon, including (and probably many) GT1 patients. The GT2/3 group is a sweet-spot for VRUS and based on data from ELECTRON trial, there's a very good chance that PSI-7977/RBV can cure these patients in 12 weeks.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up